INTRODUCTION

Leprosy (Hansen’s disease) is a dermatological and peripheral neurological disorder caused by *Mycobacterium leprae* infection that presents as skin lesions and sensory and/or motor neuron damage. It is among the leading causes of non-traumatic peripheral neuropathies worldwide. Multidrug therapy (MDT) has been distributed free of charge for registered leprosy patients on a worldwide scale in the drive toward “elimination” of leprosy as a global health problem. Declines in global incidence prompted by the MDT program have now levelled off and recent new case incidence rates indicate re-emergence in many regions that previously reported elimination. Transmission of *M. leprae* therefore continues and, worryingly, it is widely believed that a large number of cases go unreported.

In addition to provision of MDT for patients, the current pursuit of preventative measures against leprosy involves chemoprophy- laxis (single-dose rifampicin; SDR) within high-risk populations. This strategy has limitations as SDR has previously provided only a transient (2–3 years) abatement in new case detection rates. Unlike drug treatment vaccines provide active and sustained protection by promoting immune memory responses. While immunization with *M. bovis* Bacillus Calmette–Guérin (BCG) provides some protection, meta-analyses of clinical trials indicating a modest ability to prevent leprosy (26% for observational and 41% for experimental studies, respectively) and the persistence of leprosy in regions with good BCG coverage highlight that additional strategies are required. Multibacillary (MB) leprosy patients present with many disseminated skin lesions and large bacterial burdens, indicating that the strong humoral immune responses that they classically exhibit are not protective. In contrast, replication and dissemination of *M. leprae* is limited in PB leprosy patients, and despite presumed exposure to *M. leprae*, the vast majority of healthy household contacts (HHC) of MB patients appear to develop effective immunity. Thus, antigens that are recognized by PB patients or HHC are believed to be targets of an effective immune response against *M. leprae*.

The consequence of immunization on *M. leprae*-associated neuropathy has not been investigated in a controlled experimental model. Experimental *M. leprae* infection in nine-banded armadillos (*Dasypus novemcinctus*) closely recapitulates many of the structural, physiological, and functional aspects of MB (lepromatous) leprosy. Inflammation and demyelinating neuropathy are observed during histopathological inspection of infected nerves and a nerve function deficit can be detected using electrophysiology. The progression of small sensory neuropathies can be determined by immunohistochemical staining, alongside morphological and quantitative assessment, of small sensory fibers in skin punch.
The current investigation used a reverse vaccinology approach to develop a defined subunit vaccine capable of reducing \textit{M. leprae} burden when provided prophylactically to mice. We then used cutting edge neurological assays to assess the impact of post-exposure immunization on peripheral and cutaneous small sensory fibers, with particular regard to immune-mediated nerve damage, during experimental infection in armadillos. Our data indicate the development of a safe vaccine with the potential to limit the progression of \textit{M. leprae} infection to leprosy.

**RESULTS**

Immunization with select antigens reduces \textit{M. leprae} infection

Replication and dissemination of \textit{M. leprae} is limited in PB leprosy patients and most HHC, suggesting that antigens that they recognize are potentially targets of an effective immune response against \textit{M. leprae}. We previously identified several antigens that fit this criterion.\textsuperscript{23,24} To investigate if immunization with the antigens ML2028, ML2055 and ML2380 could limit \textit{M. leprae} infection, mice were immunized with single antigens, or combinations of antigens, formulated with GLA-SE, a Toll-like receptor (TLR) 4 ligand in stable emulsion (SE). Following infection with \textit{M. leprae} significantly fewer bacteria were recovered from the footpads of immunized mice relative to the numbers recovered from unimmunized control mice (Fig. 1a; p-values <0.05). These data indicate that immunization with the selected antigens elicits responses that protect mice against \textit{M. leprae} challenge and supports their inclusion within a defined sub-unit vaccine against leprosy.

While also increasing the proportion of the population that is likely to respond, combining multiple antigens into a single fusion protein is now commonly used to provide a more consistent production process. We therefore created a single tetravalent

![Fig. 1](image_url) Induction of protective anti-\textit{M. leprae} responses by recombinant antigens formulated in GLA-SE. In a mice were injected subcutaneously with antigens/GLA-SE at biweekly intervals, for a total of three immunizations. One month after the last immunization mice were infected with $1 \times 10^5 \textit{M. leprae}$ in each foot, and bacterial burdens determined 12 months later. Results are shown as mean and s.e.m. Mann–Whitney test was used to calculate p-values between each group; n = 7 per group. In b, mice were injected, or not, with BCG vaccine then 1 month later were subsequently injected subcutaneously with LepVax (at biweekly intervals if immunized more than once). Serum and spleens were collected 1 month after the final immunization to determine antigen-specific immune responses Top panel, LEPI-specific serum IgG1 and IgG2c titers were determined by ELISA. Middle and bottom panels, single-cell suspensions were prepared from each spleen and incubated with 10 ng/ml indicated protein (BCG = BCG lysate; MLCS = \textit{M. leprae} cell sonicate), then culture supernatants collected 72 h later and IFN\textgamma content determined by ELISA. Responses were corrected by the subtraction of the IFN\textgamma concentration observed in the wells of unimmunized mice. Results are shown as mean and s.e.m; n = 5 per group. Data are representative of two independent experiments. In c, mice were immunized with a mixture of GLA-SE and either recombinant antigens represented in LepVax or with LepVax (either two or three times at biweekly intervals), or with heat-killed \textit{M. leprae} (HKML) alone (no exogenous adjuvant added). One month after the last immunization mice were infected with $1 \times 10^5 \textit{M. leprae}$ in each foot, and bacterial burdens determined 12 months later. Results are shown as mean and s.e.m. Mann–Whitney test was used to calculate p-values between each group; n = 10 per group. *p-value < 0.05 and **p-value < 0.01 versus unimmunized control.
Immunization with LepVax reduces *M. leprae* burdens

We hypothesized that immunization with LepVax would limit bacterial growth, and therefore evaluated its ability to protect against experimental *M. leprae* infection. Mice were immunized then infected with *M. leprae* in the footpad. When assessed 12 months later the bacterial burdens of mice immunized with LepVax were approximately 85% lower than those observed in mice that were injected with the GLA-SE adjuvant formulation alone (Supplementary Figure 1; *p*-value < 0.05). Immunization with LepVax elicited protection equivalent to the mixture of its individual components, and provided protection when injected two or three times (Fig. 1c; *p*-values < 0.05 versus unimmunized). Statistical analyses between the 2× and 3× LepVax-immunized groups, and the 2×LepVax and HKML-immunized groups, indicates that they are not significantly different (*p*-values = 0.07 and 0.14, respectively), but the 3× LepVax and HKML-immunized groups are (*p*-value < 0.01). The reason for this vagrancy is unclear. Irrespective of this, our experimental data indicate that the defined subunit LepVax vaccine induces immune responses that significantly limit *M. leprae* infection.

Immunization with LepVax delays motor nerve function impairment

Many clinicians fear that generation of an inflammatory immune response by vaccination will precipitate leprosy, or leprosy reactions, in infected individuals. Given that the hallmark of leprosy is nerve damage, we evaluated the impact of immunization in nine-banded armadillos. To mimic asymptomatic *M. leprae* infection, a situation that is likely common in leprosy hyper-endemic regions, armadillos were first infected, then immunized and monitored (Fig. 2). Infected, but untreated armadillos, began to show nerve conduction deficits as early as 4 months after inoculation, and all of the control armadillos had exhibited at least some measurable deficit by 12 months (Fig. 3a). We noticed that in the early stages of disease development conduction deficits could fluctuate and be transient. To account for these fluctuations, we also assessed onset of sustained conduction deficit as defined by exhibiting abnormal readings for three consecutive months. The variable nature of *M. leprae* infection in these outbred animals became apparent using this parameter, with sustained nerve conduction deficits occurring over a wide range of 6–22 months after infection and 2 of 12 (17%) infected armadillos not actually demonstrating persistent alterations (Fig. 3a). In comparison to previously established compound motor action potential (CMAP) amplitude data in uninfected armadillos (0.9 mV ± 2 SD), a lower CMAP was observed among *M. leprae*-infected animals and this continued to decline over time. Interestingly, BCG immunization of already infected animals led to precipitation of nerve damage. While onset of conduction deficits in BCG vaccinated armadillos occurred at the same time as control untreated animals (Fig. 3a), sustained conduction deficits were more rapidly observed in BCG-vaccinated armadillos than control untreated animals (Fig. 3b). The extent of the dissemination was significant enough that 27% (3 of 11) of the BCG immunized armadillos had to be removed from the study. In stark contrast, LepVax immunization delayed the onset of motor nerve conduction abnormality and reduced the proportion

---

**Fig. 2.** Experimental set-up to examine post-exposure immunoprophylaxis in *M. leprae*-infected armadillos. Armadillos underwent intravenous inoculation with *M. leprae*, then 1 month later were: left untreated (unimmunized); immunized with BCG (BCG) one time; immunized with ID93 + GLA-SE, for a total of three times at monthly intervals or; immunized with LepVax (LEP-F1 + GLA-SE), for a total of three times at monthly intervals. The animals were monitored for compound muscle action potential (CMAP) and motor nerve conduction velocity (NCV) at monthly intervals, underwent three mm skin punches 16 months, and had their posterior tibial nerves (TN) biopsied at 28 months, after *M. leprae* inoculation. The photograph is the authors own.
of animals that developed sustained damage (Fig. 3a, b). The CMAP showed a moderate, but significant, improvement in LepVax immunized animals 24 months after infection (Fig. 3c; p-value < 0.05). The improvement generated by LepVax immunization was not attributable to an adjuvant impact because armadillos treated with the tuberculosis vaccine ID93 + GLA-SE did not exhibit any benefits (Fig. 3a, b). Taken together, these data reveal that LepVax immunization of infected armadillos delayed and alleviated the \textit{M. leprae}-induced motor nerve damage. Thus, when provides in a post-exposure setting, unlike BCG, LepVax delays and alleviates \textit{M. leprae}-induced motor nerve damage.

Enumeration and physical characterization of tibial nerves

Having demonstrated that LepVax immunization preserved motor nerve function, we then determined its impact on sensory nerves.

![Graph](image)

**Fig. 3**  Immunization with LepVax delays \textit{M. leprae}-induced motor nerve damage. Armadillos were monitored for compound muscle action potential (cMAP) and motor nerve conduction velocity (NCV) at monthly intervals following infection and immunization. In a, the first month at which each animal first showed an abnormal nerve conduction was recorded and in b the time at which three consecutive abnormal readings were obtained for each particular animal is noted. The cumulative percent for each group is shown, and data shown are from one of two similar experiments. In c, CMAP measurements from 24 months after infection are shown. Each point depicts the data from a single armadillo, while the box and vertical bars show the mean and s.e.m, respectively. *p-value < 0.05 versus unimmunized, infected control animals.
Electron microscopic examination of peripheral nerves revealed intact and fragmented *M. leprae* within myelinated axons, Remak Schwann cells and in axoplasm from infected unimmunized and LepVax immunized animals (Fig. 4a). In comparison to the axons from uninfected animals (Fig. 4a, panel i) the axons from infected armadillos exhibited intra axonal edema with loosening of axonal contents (Fig. 4a, panels ii and iii). Although an occasional degenerating Remak bundle and macrophages were identified in infected armadillos, no obvious lymphocytic cell infiltration was observed (Fig. 4a, panels iv, v and vi). Similar to humans, in armadillos the Remak bundles of tibial nerve predominantly carried single axons irrespective of group (Fig. 4b, uninfected: 44%, infected: 43%, immunized: 53%).

Degenerating Remak Schwann cells were only rarely observed in either uninfected or infected, LepVax-immunized armadillos (<2%). This contrasted with the increase to 5% presence of empty denervated Remak in infected, unimmunized animals. In the uninfected animals, the axon was more compact (481.2 ± 7.4 nm) than those observed in infected armadillos, no obvious lymphocytic cell infiltration was observed (Fig. 4a, panels iv, v and vi). Similar to humans, in armadillos the Remak bundles of tibial nerve predominantly carried single axons irrespective of group (Fig. 4b, uninfected: 44%, infected: 43%, immunized: 53%).

Degenerating Remak Schwann cells were only rarely observed in either uninfected or infected, LepVax-immunized armadillos (<2%). This contrasted with the increase to 5% presence of empty denervated Remak in infected, unimmunized animals. In the uninfected animals, the axon was more compact (481.2 ± 7.4 nm) than those observed in infected armadillos, no obvious lymphocytic cell infiltration was observed (Fig. 4a, panels iv, v and vi). Similar to humans, in armadillos the Remak bundles of tibial nerve predominantly carried single axons irrespective of group (Fig. 4b, uninfected: 44%, infected: 43%, immunized: 53%).

**Characterization and enumeration of cutaneous nerves of distal leg**

The cutaneous innervation in *M. leprae*-infected armadillos followed a pattern comparable to that observed in leprosy patients, with the axons shredding the Schwann cell covering before entering the epidermis (Fig. 5a). In uninfected animals the distal skin exhibited dense epidermal nerve fibers and, regardless of if they had been immunized or not, the epidermal nerve fiber density was not significantly altered in *M. leprae*-infected animals (Fig. 5b). Remak Schwann cells of the cutaneous nerves in the distal leg were, however, denser in the infected armadillos in comparison to uninfected armadillos, suggesting that proliferation...
of the Schwann cells was occurring in response to *M. leprae* infection at cooler distal sites (Fig. 5c,d; \( p \)-value = 0.02). Immunization with LepVax slightly reduced the Remak Schwann cells density in the skin relative to unimmunized, infected armadillos, indicating that the vaccine certainly did not exacerbate sensory nerve involvement but rather provided some protective benefit to the cutaneous nerves.

**DISCUSSION**

Despite the impact of WHO-MDT on global prevalence, drug treatment of patients is unlikely to be sufficient to eliminate leprosy and further efforts are required to prevent its re-emergence. Targeting at-risk populations, amongst whom many individuals may already be infected with *M. leprae*, with an effective vaccine appears to be more a tenable long lasting strategy. The potential application of a vaccine under these circumstances has met with some reservations because neurological injury continues in patients even after the commencement of MDT and can be exacerbated during immune-mediated, inflammatory reactional episodes. It is therefore of particular importance to not only show that a vaccine can limit *M. leprae* infection but also does not exacerbate nerve damage. Our data identified antigens that can confer protection in a small animal system and this led to the generation of LepVax, a chimeric fusion protein composed of four distinct protein moieties in conjunction with the TLR4-based adjuvant formulation GLA-SE. Prophylactic immunization of mice with LepVax significantly inhibited *M. leprae* outgrowth. Use of LepVax in the experimental post-exposure setting involving *M. leprae*-infected armadillos demonstrated not only its safe use but efficacy against motor nerve damage.

It is known that *M. leprae* infection in nine-banded armadillos (*Dasypus novemcinctus*), the only other host of *M. leprae* that closely recapitulates many of the structural, physiological, and functional aspects of leprosy observed in humans,\(^{11-14,25}\) Almost 70% of the armadillos manifest a lepromatous-type response to *M. leprae*. Monitoring studies of MB leprosy patients identified that approximately 40% had a reaction, neuritis, or new nerve function impairment event within 2 years following diagnosis that was detectable by monofilament testing and voluntary muscle testing.\(^{26}\) Nerve function was evaluated at each visit using nerve conduction, quantitative thermal sensory testing and vibrometry, dynamometry, and sub-clinical neuropathy was considered extensive (20–50%), even in patients who did not develop an

![Fig. 5 Morphometry of cutaneous nerves in armadillos. 3 mm skin punches were made at the distal leg in uninfected armadillos (n = 9) and in infected armadillos that were either unimmunized (n = 11) and LepVax-immunized (n = 11) at the 16th month after *M. leprae* inoculation. In a, the cutaneous innervation exhibits a comparable pattern to that observed in humans. In b, intraepidermal nerve fiber densities were measured. Results are shown as mean and s.e.m. In c, the brownish strands of Remak Schwann cell bundles in the dermis exhibiting Schwann cell nuclei (broken arrows) can be observed. In d, Schwann cells were enumerated using stereological optical fractionator probe. Results are shown as mean and s.e.m.](image-url)
studies have shown that partially play a role in the initiation of neuropathogenesis during early cells by altering host-gene expression, and the bacterially localized due to the blood nerve barrier, and Schwann cells provide a of any clinical signs. Indeed, during lepromatous leprosy the of M. leprae localization and proliferation.

risk. While a PB presentation is preferred over MB disease, the disease in some individuals, with speculation that infected but controlled system. Anecdotal reports, and now clinical evidence, on

published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2018) 12 "pre-clinical silent neuropathy"

"post-exposure prophylaxis"

MATERIALS AND METHODS

Ethics statement

Mouse experiments were conducted in accordance with procedures approved by either the Infectious Disease Research Institute (IDRI), National Institute of Infectious Diseases (NIID) or National Hansen's Disease Program (NHDP) Animal Care and Use Committee, respectively. Armadillo experiments were conducted in accordance with procedures approved by the National Animal Care and Use Committee. Animals were distributed randomly in different cages with group sizes calculated to allow minimal animal usage required to provide proper statistical analysis based on estimates of anticipated variation of rodent models of M. leprae infection and on prior experience with the experimental systems. The investigators were not blinded to analysis.

Mice and immunizations

Female, 6–8 week old wild type C57BL/6 (B6) mice were purchased from Charles River Laboratories (Wilmington, MA). Mice were immunized with recombinant protein formulated with saline, SE or glucopyranosyl lipid adjuvant (GLA-SE). Mice were immunized up to three times by subcutaneous (s.c) injection of 0.1 ml volume at the base of the tail at 2-week intervals. Investigators were not blinded to the status of each treatment group. Mice were maintained in specific pathogen-free conditions and all procedures were approved by the pertinent institutional animal care and use committees (IDRI and NHDP).

Antibody responses

Mouse sera were prepared following collection of retro-orbital blood into microtainer serum collection tubes (VWR International, West Chester, PA) followed by centrifugation at ~135g for 5 min. Each serum was then analyzed by antibody capture ELISA. Briefly, ELISA plates (Nunc, Rochester, NY) were coated with 1 μg/ml recombinant antigen in 0.1 M bicarbonate buffer and blocked with 1% BSA-PBS. Then, in consecutive order and

outcome event. CMAP velocities were frequently affected, with velocity impaired in up to 43% of motor nerves. We have previously demonstrated that the distal limb in armadillos exhibit a length dependent type of innervation similar to that observed in patients, with denser innervation at the proximal sites than in the distal leg. Experiments inoculated armadillos developed conduction abnormalities that manifested as depressed CMAP amplitude (<0.9 mV), or even total conduction block similar to observations in humans. Peripheral nerves are immune privileged due to the blood nerve barrier, and Schwann cells provide a safe niche for M. leprae survival, propagation and initial colonization, allowing for the long incubation period before manifestation of any clinical signs. Indeed, during lepromatous leprosy the sequence of sensory loss follows relative body temperatures with cooler areas providing the most favorable environment for M. leprae. In conclusion, we have developed a single chimeric fusion protein that, when used in conjunction with the clinically approved GLA-SE formulation in a classical prophylactic immunization strategy, provides protection against M. leprae challenge of mice. Furthermore, by extending our studies into armadillos we were able to advance our understanding of leprosy per se by showing that M. leprae infection induces neuropathy that mimics the pre-clinical silent neuropathic situation that develops in leprosy patients. In stark contrast to BCG vaccination, the provision of LepVax after M. leprae infection (post-exposure immunoprophylaxis) was not only safe but efficacious, alleviating sensory nerve damage and both delaying and alleviating motor nerve damage in animals infected with high doses of M. leprae. Advancement of the LepVax vaccine to clinical testing appears prudent, with the potential to provide sustained, active protection against M. leprae infection. This represents a critical step toward the true elimination of leprosy.
following washes in PBS/Tween20, serially diluted serum samples, anti-mouse IgG, IgG1 or IgG2c-HRP (all Southern Biotech, Birmingham, AL) and ABTS-H2O2 (Kirkegaard and Perry Laboratories, Gaithersburg, MD) were added to the plates. Plates were analyzed at 405 nm (ELx808, Bio-Tek Instruments Inc, Winooski, VT). Endpoint titer was determined as the last dilution to render a positive response, determined as two times the mean optical density of the replicates derived from sera from unimmunized mice in Prism software (GraphPad Software, La Jolla, CA).

Antigen stimulation and cytokine responses
Single-cell suspensions were prepared by disrupting spleens between frosted slides. Red blood cells were removed by lysis in 1.66% NH4Cl solution, then mononuclear cells enumerated by ViaCount assay with a PCA system (Guava Technologies, Hayward, CA). Single-cell suspensions were cultured at 2 x 10^5 cells per well in duplicate in a 96-well plate (Corning Incorporated, Corning, NY) in RPMI-1640 supplemented with 5% heat-inactivated fetal calf serum and 50,000 Units penicillin streptomycin (Invitrogen). Cells were cultured in the presence of 10 µg/ml antigen for 72–96 h, after which culture supernatants were harvested and cytokine content assessed. IFNγ concentrations within culture supernatants were determined by ELISA performed according to manufacturer’s instructions (ebiScience) and optical density was determined using an ELx808 plate reader.

Determination of bacterial burden in mice
To assess M. leprae growth, live M. leprae bacilli (Thai-53 strain) were purified from the footpads of nu/nu nude mice at NHDP or NID. Mice were inoculated with 1 x 10^4 bacilli by s.c. injection into each foot pad. Foot pads were harvested 12 months later and the bacilli were enumerated by direct microscopic counting of acid-fast bacilli according to the method of Shepard and McRae.40

M. leprae infection of armadillos
The majority of the armadillos used in this study were genetically identical siblings that were allocated across the different treatment groups, thereby providing additional statistical power to the study. All armadillos were inoculated by intravenous injection with a suspension of 1 x 10^5 viable M. leprae derived from passage in nude mice.51

Characterization of peripheral nerves of armadillos by electron microscopy
The nerves were fixed for 48 h in 4% paraformaldehyde -3% glutaraldehyde and then transferred to 0.1 M Sorensen’s phosphate buffer. Sections were post-fixed with osmium, embedded in plastic and one-micron thick sections were made and stained with 1% toluidine blue. Thin 70-nm sections were post-fixed in 2% paraformaldehyde/lysine/periodate for 24 h, then processed and stained with uranyl acetate (2.5% in 50% ethanol) and lead citrate (3%). The nerve sections were examined with a digital Zeiss Libra 120 electron microscope and Remak bundles identified using previously specified criteria.43,44 Point lists were randomly made at 4000 x to scan different sites in the sections and a minimum of 50 digital photographs were captured at a magnifications of 8000x to 16000x. Images were uploaded onto iTEM program (Olympus soft imaging), and Remak Schwann cells carrying unmethylated axons were identified by specified criteria.49,50 An individual linear array was used to measure the mean axonal and Schwann cell diameter (nm, shortest distance) and the total number of unmethylated axons per Remak Schwann cell quantified according to the established methodology.20,46

Immunohistochemistry of skin sections
Skin biopsies were fixed in 2% paraformaldehyde/lysine/periodate for 24 h, sectioned with a sliding microtome into 50-µm thick, frozen, vertical, free-floating sections, which were then placed in 24-well tissue culture plates for immunostaining. Each skin section was incubated with the following primary antibodies diluted in blocking buffer: anti-PGP 9.5 (Chemicon, Temecula, CA), as a pan axonal marker, and mouse anti-p75 nerve growth factor receptor (Millipore), as a phenotypic marker for Schwann cells. Nonspecific binding of secondary antibodies was prevented by incubating sections with 4% normal goat serum diluted in 1.0% Triton X-100, 0.5% nonfat powdered milk in Tris-buffered saline (pH 7.4)). Sections were rinsed in Tris-buffered saline (pH 7.4) and transferred to secondary antibodies secondary antibodies (diluted 1:100 in blocking buffer) included goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) and goat anti-mouse IgG (Vector Laboratories). The sections were then incubated with Avidin–Biotin Complex solution (Vector Laboratories), and color was developed with chromogens. PGP 9.5-stained sections were developed with blue/grey (Vector SG substrate) chromophore and p75-stained sections with diaminobenzidine. One percent eosin and Mayer’s hematoxylin were used as counterstains.

Morphometry and histomorphometry of Schwann cells
Intraepidermal nerve fiber densities (IENFD) in skin biopsies were determined using established counting rules19,47,48 and IENFD was expressed as fibers/mm. Schwann cell bands within the dermis were identified in the skin sections by the presence of brown colored cytoplasmic staining by p75 in the setting of elongated blue-staining nuclei (counter stained with Mayer’s hematoxylin). The Schwann cell nuclei were visualized and quantified using a design-based stereology methodology. The area of interest was defined as the dermal region extending from the epidermal/dermal junction to a dermal depth of 2000 µm. A contour was made at the area of interest under an ×25/0.75 Plan–NeoFluor objective of a Zeiss light microscope and the cells were counted using ×63/1.40, oil Plan–NeoFluor objective. A sampling grid 200 mm × 150 mm, with a dissector height of 15 mm and guard zones of 2 mm was used and the absolute numbers of Schwann cells were obtained using the “DAT” files of optical fractionator probe of Stereo Investigator (MBF Bioscience).47,55 The Schwann cell density was determined as number of cells/mm². The sampling design achieved a Gundersen coefficient of error 0.1. All morphometric measurements were conducted in a double-blinded, coded manner with no knowledge of the identifying data.

Statistics
No statistical methods were used to ensure adequate power, but sample sizes were selected based on prior experience to achieve statistical significance with the lowest number of animals. The non-parametric Kruskal–Wallis analysis of variance test was used to compare the IFNγ levels among all of the groups. The p-values for studies resulting in normally distributed data including two groups were determined using the Student’s t-test. Where more than two groups were compared, p-values were attained by ANOVA analyses. Data were log-transformed for non-normal data sets prior to analysis. Statistics were generated using MS Excel (Microsoft Corporation, Redmond, WA) or Prism software (GraphPad Software, Inc., La Jolla, CA). Statistical significance was considered when the p-values were <0.05.

Data availability
The underlying data reported in this paper are available from the corresponding author upon reasonable request.

ACKNOWLEDGEMENTS
We thank Alex Picone, Richard Cabullos, Raodoh Mohamath and Julie Vergara for technical assistance producing the antigens used and performing mouse vaccine experiments, along with Drs. Paul Saunderson, Warwick Britton and Patrick Brennan for invaluable discussion and comments throughout the development process. This research was funded by grants from the American Leprosy Missions, Order of Malta (MaltaLep), The Heiser Program for Research in Leprosy and Tuberculosis of The New York Community Trust, Renaissance Health Service Corporation, and U.S. Department of Health and Human Services (DHHS), Health Resources and Services Administration (HRSA), Healthcare Systems Bureau (HSB), National Hansen’s Disease Programs.

AUTHOR CONTRIBUTIONS
Experimental design: M.S.D., G.J.E., T.P.G., R.W.T., S.G.R. Mouse experiments: M.S.D., T.P. G., Y.M., M.M. Armadillo experiments: M.T.P., R.S., R.W.T. Nerve analyses: G.J.E., K.C., M. P. Data analyses: M.S.D., M.T.P., G.J.E., T.P.G., M.P., R.W.T. Manuscript preparation: M.S. D., M.T.P., G.J.E., R.W.T., S.G.R.

ADDITIONAL INFORMATION
Supplementary Information accompanies the paper on the npj Vaccines website (https://doi.org/10.1038/s41541-018-0050-z).

npj Vaccines (2018) 12 Published in partnership with the Sealy Center for Vaccine Development

Pre- and post-exposure immune prophylaxis for leprosy
MS Duthe et al.
Complying interests: S.G.R. is a founder of, and holds an equity interest in, Immune Design, a licensee of certain rights associated with GLA. S.G.R. and M.S.D. hold a patent on the development of subunit vaccines for leprosy. The other authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES

1. Richardus, J. H. & Habbema, J. D. The impact of leprosy control on the transmission of M. leprae: is elimination being attained? Lepr. Rev. 78, 330–337 (2007).

2. Katoch, K. et al. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine 22, 3649–3657 (2004).

3. Smith, W. C., van Brakel, W., Gilis, T., Saunderson, P. & Richardus, J. H. The missing millions: a threat to the elimination of leprosy. PLoS Negl. Trop. Dis. 9, e0003658 (2015).

4. Moet, F. J., Schuring, R. P., Pahan, D., Oskam, L. & Richardus, J. H. The prevalence of previously undiagnosed leprosy in the general population of northwest Bangladesh. PLoS Negl. Trop. Dis. 2, e198 (2008).

5. Bakker, M. I. et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am. J. Trop. Med. Hyg. 72, 443–448 (2005).

6. Smith, C. M. & Smith, W. C. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MLEP2 Study Group. Mucosal Immunology of Leprosy. J. Infect. 41, 137–140 (2002).

7. Setia, M. S., Steinmaus, C., Ho, C. S. & Rutherford, G. W. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect. Dis. 6, 162–170 (2006).

8. Duppere, N. C. et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans. R. Soc. Trop. Med. Hyg. 102, 631–638 (2008).

9. Cunha, S. S. et al. BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. PLoS Negl. Trop. Dis. 2, e167 (2008).

10. Merle, C. S., Cunha, S. S. & Rodrigues, L. C. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines 9, 209–222 (2010).

11. Sharma, R. et al. The armadillo: a model for the neuropathy of leprosy and potentially other neurodegenerative diseases. Dis. Models Mech. 6, 19–24 (2013).

12. Scollard, D. M. The biology of nerve injury in leprosy. Lepr. Rev. 79, 242–253 (2008).

13. Truman, R. W. et al. The armadillo as a model for peripheral neuropathy in leprosy. J. Arak. J. 54, 304–314 (2014).

14. Loughey, W. J. et al. Is leprosy spreading among nine-banded armadillos in the southeastern United States? J. Wildl. Dis. 45, 145–152 (2009).

15. Stors, E. E., Walsh, G. P., Burchfield, H. P. & Binford, C. H. Leprosy in the armadillo: new model for biomedical research. Science 183, 851–852 (1974).

16. Job, C. K., Kirchheimer, W. F. & Sanchez, R. M. Variable lepromin response to Mycobacterium leprae in resistant armadillos. Int. J. Lepr. Other Mycobact. Dis. 51, 347–353 (1983).

17. Job, C. K. & Truman, R. Comparative study of Mitsuda reaction to nude mouse and armadillo lepromin preparations using nine-banded armadillos. Int. J. Lepr. Other Mycobact. Dis. 68, 18–22 (2000).

18. Scollard, D. M. et al. The continuing challenges of leprosy. Clin. Microbiol. Rev. 19, 338–381 (2006).

19. Ebenezer, G. J., Hauer, P., Gibbons, C., McGrath, J. C. & Polydefkis, M. Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J. Neuropathol. Exp. Neurol. 66, 1059–1073 (2007).

20. Ebenezer, G. J. et al. Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 130, 2703–2714 (2007).

21. England, J. D. et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electromydiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 1, 14–22 (2009).

22. Polydefkis, M. et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 58, 115–119 (2002).

23. Sampaio, L. H. et al. Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development. BMC Infect. Dis. 11, 26 (2011).

24. Duthie, M. S. et al. Antigen-specific T-cell responses of leprosy patients. Clin. Vaccin. Immunol. 15, 1659–1665 (2008).

25. Storns, E. E., Walsh, G. P., Burchfield, H. P. & Binford, C. H. Leprosy in the armadillo: new model for biomedical research. Science 183, 851–852 (1974).

26. van Brakel, W. H. et al. Early diagnosis of neuropathy in leprosy—comparing diagnostic tests in a large prospective study (the INFIR cohort study). PLoS Negl. Trop. Dis. 2, e212 (2008).